Dosage forms and methods for oral delivery of progesterone
US6544553B1 · kind B1 · utility
75Cited by
19References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 1999 |
| Grant date | Apr 8, 2003 |
| Priority date | — |
| Expiry date | Dec 28, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4808
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an oral dosage form suitable to deliver a combined dosage of progesterone and which upon delivery through the gastrointestinal tract provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form comprising from about 25 mg to about 500 mg micronized progesterone in a solid polyethylene glycol carrier having an average molecular weight of from about 1000 to 10,000 and constituting at least about 30% of said first solid form; and (b) a second solid form comprising an estrogen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.